{
    "root": "661ac178-ebff-4094-8647-09c7ba0475e1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe",
    "value": "20250210",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SODIUM LAURETH-12 SULFATE",
            "code": "8M492LDU23",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        }
    ],
    "indications": {
        "text": "ezetimibe tablets indicated : combination statin , alone additional low-density lipoprotein cholesterol ( ldl-c ) lowering therapy possible , adjunct diet reduce elevated ldl-c adults primary hyperlipidemia , including heterozygous familial hypercholesterolemia ( hefh ) . combination statin adjunct diet reduce elevated ldl-c pediatric patients 10 years age older hefh . combination fenofibrate adjunct diet reduce elevated ldl-c adults mixed hyperlipidemia . combination statin ldl-c lowering therapies , reduce elevated ldl-c levels adults pediatric patients 10 years age older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet reduction elevated sitosterol campesterol levels adults pediatric patients 9 years age older homozygous familial sitosterolemia . ezetimibe tablets used combination statin , fenofibrate , ldl-c lowering therapies , refer prescribing information products information safe effective .",
        "doid_entities": [
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            },
            {
                "text": "sitosterolemia (DOID:0090019)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0090019"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose ezetimibe tablet 10 mg orally daily , administered without food . dose missed , take missed dose soon possible . double next dose . assess ldl-c clinically appropriate , early 4 weeks initiating ezetimibe tablet . administer ezetimibe tablet least 2 hours 4 hours bile acid sequestrant [ ( 7 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ezetimibe tablets usp , 10 mg supplied white off-white , capsule-shaped tablets debossed \u201c aa69 \u201d one side plain side . supplied follows : bottles 30 : ndc 69238-1154-3 bottles 90 : ndc 69238-1154-9 bottles 500 : ndc 69238-1154-5 bottles 1000 : ndc 69238-1154-1 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "ezetimibe tablets contraindicated patients known hypersensitivity ezetimibe excipients ezetimibe tablets . hypersensitivity including anaphylaxis , angioedema , rash urticaria reported [ ( 6.2 ) ] . used combination statin , fenofibrate , ldl-c lowering therapy , ezetimibe contraindicated patients statin , fenofibrate , ldl-c lowering therapy contraindicated . refer prescribing information products list [ ( 5.1 ) ] .",
    "indications_original": "Ezetimibe tablets are indicated:\n                  \n                     In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).\n                     In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.\n                     In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.\n                     In combination with a statin and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.\n                  \n                  When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.",
    "contraindications_original": "The recommended dose of ezetimibe tablet is 10 mg orally once daily, administered with or without food.\n                     If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.\n                     Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablet.\n                     Administer ezetimibe tablet at least 2 hours before or 4 hours after administration of a bile acid sequestrant\u00a0[see Drug Interactions (7\n                           )].",
    "warningsAndPrecautions_original": "Ezetimibe Tablets USP, 10 mg are supplied as white to off-white, capsule-shaped tablets debossed with \u201cAA69\u201d on one side and plain on other side. \n                  They are supplied as follows:\n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-1154-3\n                  Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-1154-9\n                  Bottles of 500:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-1154-5\n                  Bottles of 1000: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 69238-1154-1\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash and urticaria have been reported [see Adverse Reactions (6.2)].\n                  When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1)].",
    "drug": [
        {
            "name": "Ezetimibe",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        }
    ]
}